Correction: End-ischemic hypothermic oxygenated perfusion for extended criteria donors in liver transplantation: a multicenter, randomized controlled trial—HOPExt (Trials, (2023), 24, 1, (379), 10.1186/s13063-023-07402-0)

0Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Following publication of the original article [1], we have been informed that Table 1 has been misaligned during typesetting. (Table presented.) Schedule of enrolment, interventions, and assessments in the HOPExt trial 1patient characteristics: age, gender, height, weight, BMI, blood group, cause of cirrhosis, indication for transplantation, medical history (diabetes mellitus, arterial hypertension, transjugular intrahepatic portosystemic shunt) pretransplant status of residence (home, hospital ward or intensive care unit (ICU)) 2Randomization will be performed after the harvesting team has macroscopically assessed the graft and confirmed that the graft will be harvested. After checking the inclusion and non-inclusion criteria an online randomization tool will be used. Randomization will be stratified by center and MELD score at the time of transplantation with a cut-off of 30 3Clinical examination: vital signs (temperature, blood pressure, heart rate), body weight, height, BMI 4Biological analyses: AST, ALT, GGT, Alkaline Phosphatase, bilirubin, factor V, INR, platelets, creatinine, GFR, lactates At V2 only, a pregnancy test (beta HCG) will be done for women of childbearing age 5Donor characteristics: age, gender, height, weight, BMI, blood group, length of stay in intensive care unit, cause of death, occurrence of cardiac arrest, biological test (AST, ALT, natremia) 6Parameters measured during HOPE perfusion (only in HOPE group): perfusion pressure, flow, temperature, duration of machine perfusion, perfusate oxygenation (partial pressure O2) and CO2 content (partial pressure CO2) at the beginning and at the end of machine perfusion; perfusate AST and ALT, LDH, hyaluronic acid, lactate levels at 30 minutes and at the end of machine perfusion 7Bacteriological and fungal samplings will be taken on static storage solution (IGL-1) at the end of the back-table in both groups, and of the perfusion solution at the end of machine perfusion for HOPE group 8Intra-operative data: surgical technique of transplantation (piggy-back vs. vena cava resection), length of procedure, transfusion needs (fresh frozen plasma, red blood cell, thrombocyte concentrate), occurrence of post-reperfusion syndrome (decrease of 50% of the median arterial pressure during the 5 minutes after the revascularisation), cold ischemia time, circulatory support at the end of transplantation (noradrenaline (mg/h)) 9A biopsy will be taken on the back-table before machine perfusion in both study groups, immediately after liver machine perfusion in the HOPE group, and after reperfusion of the liver in both groups 103ml sample will be taken from machine perfusion solution during HOPE perfusion (only in HOPE group), at 30 minutes and at the end of machine perfusion The original article has been corrected.

Cite

CITATION STYLE

APA

Pradat, P., Pantel, S., Maynard, M., Lalande, L., Thevenon, S., Adam, R., … Lesurtel, M. (2023, December 1). Correction: End-ischemic hypothermic oxygenated perfusion for extended criteria donors in liver transplantation: a multicenter, randomized controlled trial—HOPExt (Trials, (2023), 24, 1, (379), 10.1186/s13063-023-07402-0). Trials. BioMed Central Ltd. https://doi.org/10.1186/s13063-023-07471-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free